PL362964A1 - Szczepionka - Google Patents
SzczepionkaInfo
- Publication number
- PL362964A1 PL362964A1 PL01362964A PL36296401A PL362964A1 PL 362964 A1 PL362964 A1 PL 362964A1 PL 01362964 A PL01362964 A PL 01362964A PL 36296401 A PL36296401 A PL 36296401A PL 362964 A1 PL362964 A1 PL 362964A1
- Authority
- PL
- Poland
- Prior art keywords
- vaccine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18563—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18661—Methods of inactivation or attenuation
- C12N2760/18663—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0024088A GB0024088D0 (en) | 2000-10-02 | 2000-10-02 | Novel compounds |
GB0109288A GB0109288D0 (en) | 2001-04-12 | 2001-04-12 | Novel compounds |
PCT/EP2001/011328 WO2002028426A1 (en) | 2000-10-02 | 2001-10-01 | Split enveloped virus preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
PL362964A1 true PL362964A1 (pl) | 2004-11-02 |
Family
ID=26245086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL01362964A PL362964A1 (pl) | 2000-10-02 | 2001-10-01 | Szczepionka |
Country Status (17)
Country | Link |
---|---|
US (1) | US20040028698A1 (pl) |
EP (1) | EP1322329A1 (pl) |
JP (1) | JP2004510747A (pl) |
KR (1) | KR20030055275A (pl) |
CN (1) | CN1253207C (pl) |
AR (1) | AR030829A1 (pl) |
AU (2) | AU1591402A (pl) |
BR (1) | BR0114392A (pl) |
CA (1) | CA2423610A1 (pl) |
CZ (1) | CZ2003930A3 (pl) |
HU (1) | HUP0302636A3 (pl) |
IL (1) | IL155073A0 (pl) |
MX (1) | MXPA03002890A (pl) |
NO (1) | NO20031484L (pl) |
NZ (1) | NZ525076A (pl) |
PL (1) | PL362964A1 (pl) |
WO (1) | WO2002028426A1 (pl) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE437943T1 (de) * | 1996-01-30 | 2009-08-15 | Univ California | Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung. |
BR0114392A (pt) * | 2000-10-02 | 2003-09-02 | Glaxosmithkline Biolog Sa | Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
US7588774B2 (en) | 2003-05-12 | 2009-09-15 | Becton, Dickinson And Company | Molecules enhancing dermal delivery of influenza vaccines |
US20050123550A1 (en) * | 2003-05-12 | 2005-06-09 | Laurent Philippe E. | Molecules enhancing dermal delivery of influenza vaccines |
CN1305526C (zh) * | 2003-12-29 | 2007-03-21 | 薛平 | 乙型脑炎病毒裂解疫苗及其制备方法 |
WO2006091722A2 (en) * | 2005-02-23 | 2006-08-31 | Uab Research Foundation | Alkyl-glycoside enhanced vaccination |
WO2007015441A1 (ja) | 2005-08-01 | 2007-02-08 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよび製剤 |
RU2392965C2 (ru) * | 2006-01-26 | 2010-06-27 | Пфайзер Продактс Инк. | Новые гликолипидные адъювантные композиции |
GB0622282D0 (en) * | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
WO2008093772A1 (ja) * | 2007-01-31 | 2008-08-07 | Hisamitsu Pharmaceutical Co., Inc. | 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤 |
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
DK3067064T3 (da) | 2008-12-09 | 2020-06-08 | Novavax Inc | Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf |
CA2803444A1 (en) * | 2010-06-29 | 2012-01-05 | Universite Laval | Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-l-like receptor ligand or a nod-like receptor ligand to enhance the innate immune response |
CN107050445A (zh) * | 2011-05-26 | 2017-08-18 | 葛兰素史密丝克莱恩生物有限公司 | 灭活登革热病毒疫苗 |
JP6114401B2 (ja) | 2013-10-31 | 2017-04-12 | 久光製薬株式会社 | アジュバント組成物、これを含むアジュバント製剤、及びキット |
KR20160068972A (ko) | 2013-11-15 | 2016-06-15 | 노파르티스 아게 | 잔여 세포 배양 불순물의 제거 |
FR3025107B1 (fr) | 2014-08-29 | 2018-10-05 | Calixar | Procede de preparation d'un antigene vaccinal, antigene vaccinal obtenu et utilisations |
AU2016315478B2 (en) | 2015-09-03 | 2023-07-13 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
JP7417532B2 (ja) | 2018-03-19 | 2024-01-18 | ノババックス,インコーポレイテッド | 多価インフルエンザナノ粒子ワクチン |
EP3775174A4 (en) * | 2018-03-30 | 2022-07-06 | Georgia State University Research Foundation, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES |
CN110665002B (zh) * | 2019-10-29 | 2023-01-24 | 信阳市动物疫病预防控制中心 | 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法 |
CN113804593B (zh) * | 2020-06-11 | 2024-05-24 | 北京科兴生物制品有限公司 | 一种裂解疫苗裂解效果的检测方法及应用 |
CN115996940A (zh) * | 2020-07-01 | 2023-04-21 | 免疫医疗有限责任公司 | 用于纯化生物治疗剂的洗涤剂和方法 |
CN112190705A (zh) * | 2020-09-25 | 2021-01-08 | 广州源博医药科技有限公司 | 一种rsv-sh亚单位疫苗及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1486557A (en) * | 1973-10-18 | 1977-09-21 | Flockhart & Co | Process for the preparation of pyrogen-free sub-unit vaccine |
DE2829089A1 (de) * | 1977-07-13 | 1979-02-01 | Sandoz Ag | Subunit-vakzine |
DE2750045A1 (de) * | 1977-11-09 | 1979-05-10 | Behringwerke Ag | Verfahren zur entfernung von detergentien aus virusantigensuspensionen |
FR2475572A1 (fr) * | 1980-02-11 | 1981-08-14 | Pasteur Institut | Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications |
AT405939B (de) * | 1997-02-24 | 1999-12-27 | Immuno Ag | Verfahren zur inaktivierung von lipidumhüllten viren |
HUP0101619A3 (en) * | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
AU5937901A (en) * | 2000-05-03 | 2001-11-12 | Med Immune Inc | Combination therapy of respiratory diseases using antibodies |
BR0114392A (pt) * | 2000-10-02 | 2003-09-02 | Glaxosmithkline Biolog Sa | Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv |
-
2001
- 2001-10-01 BR BR0114392-1A patent/BR0114392A/pt not_active Application Discontinuation
- 2001-10-01 PL PL01362964A patent/PL362964A1/pl unknown
- 2001-10-01 AU AU1591402A patent/AU1591402A/xx active Pending
- 2001-10-01 CA CA002423610A patent/CA2423610A1/en not_active Abandoned
- 2001-10-01 AR ARP010104630A patent/AR030829A1/es unknown
- 2001-10-01 WO PCT/EP2001/011328 patent/WO2002028426A1/en not_active Application Discontinuation
- 2001-10-01 IL IL15507301A patent/IL155073A0/xx unknown
- 2001-10-01 US US10/381,486 patent/US20040028698A1/en not_active Abandoned
- 2001-10-01 NZ NZ525076A patent/NZ525076A/en unknown
- 2001-10-01 HU HU0302636A patent/HUP0302636A3/hu unknown
- 2001-10-01 KR KR10-2003-7004718A patent/KR20030055275A/ko not_active Application Discontinuation
- 2001-10-01 AU AU2002215914A patent/AU2002215914B2/en not_active Ceased
- 2001-10-01 CN CNB018198090A patent/CN1253207C/zh not_active Expired - Fee Related
- 2001-10-01 JP JP2002532250A patent/JP2004510747A/ja active Pending
- 2001-10-01 EP EP01986267A patent/EP1322329A1/en not_active Withdrawn
- 2001-10-01 MX MXPA03002890A patent/MXPA03002890A/es unknown
- 2001-10-01 CZ CZ2003930A patent/CZ2003930A3/cs unknown
-
2003
- 2003-04-01 NO NO20031484A patent/NO20031484L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU1591402A (en) | 2002-04-15 |
US20040028698A1 (en) | 2004-02-12 |
NO20031484D0 (no) | 2003-04-01 |
WO2002028426A1 (en) | 2002-04-11 |
JP2004510747A (ja) | 2004-04-08 |
CZ2003930A3 (cs) | 2003-08-13 |
HUP0302636A3 (en) | 2008-03-28 |
MXPA03002890A (es) | 2004-12-03 |
NO20031484L (no) | 2003-05-28 |
CN1477973A (zh) | 2004-02-25 |
CN1253207C (zh) | 2006-04-26 |
HUP0302636A2 (hu) | 2003-11-28 |
AU2002215914B2 (en) | 2004-08-19 |
BR0114392A (pt) | 2003-09-02 |
CA2423610A1 (en) | 2002-04-11 |
IL155073A0 (en) | 2003-10-31 |
EP1322329A1 (en) | 2003-07-02 |
NZ525076A (en) | 2004-09-24 |
WO2002028426A8 (en) | 2002-06-06 |
KR20030055275A (ko) | 2003-07-02 |
AR030829A1 (es) | 2003-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB0020953D0 (en) | Vaccine | |
HUP0301043A3 (en) | Vaccine | |
IL155072A0 (en) | Vaccine | |
IL155282A0 (en) | Vaccines | |
AU8189501A (en) | Vaccine composition | |
HUP0302117A3 (en) | Vaccine composition | |
GB0020089D0 (en) | Vaccine Composition | |
AU1591402A (en) | Vaccine | |
GB0130215D0 (en) | Vaccine | |
GB0407935D0 (en) | Vaccine | |
GB0024200D0 (en) | Component vaccine | |
EP1423141A4 (en) | VACCINE | |
GB0121171D0 (en) | Vaccine | |
GB0014288D0 (en) | Vaccine | |
GB0014845D0 (en) | Vaccine | |
GB0026334D0 (en) | Vaccine | |
GB0025694D0 (en) | Vaccine | |
GB0003082D0 (en) | Vaccine | |
GB0015722D0 (en) | Vaccine | |
GB0006693D0 (en) | Vaccine | |
GB0004533D0 (en) | Vaccines | |
GB0027433D0 (en) | Vaccine component | |
GB0015935D0 (en) | Vaccine | |
GB0020693D0 (en) | Vaccine | |
GB0025575D0 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |